Lantheus (LNTH) AI Stock Analysis

• Market Cap: $6.82B
• Dividend Yield: N/A
• Average Volume (3M): 799.44K
• Price to Earnings (P/E): 23.1
• Beta (1Y): 0.42
• Revenue Growth: 18.32%
• EPS Growth: -5.33%
• Country: US
• Employees: 808
• Sector: Healthcare
• Sector Strength: 64
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.37
• Shares Outstanding: 68,480,310
• 10 Day Avg. Volume: 791,827
• 30 Day Avg. Volume: 799,443
• PEG Ratio: 0.04
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4.36
• Price to Cash Flow (P/CF): 10.60
• P/FCF Ratio: 6.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $127.13
• Price Target Upside: 22.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

Lantheus earns a strong overall score due to its robust financial performance, strategic acquisitions, and optimistic future guidance. While technical indicators show mixed signals, and valuation is moderate, the company's strategic initiatives and strong financial health suggest a positive outlook.

Positive Factors

Market Position

Despite competition, PYLARIFY has maintained its market leading position.

Revenue Growth

Definity revenues in 4Q beat consensus and estimates by 14% and 9%, respectively.

Strategic Acquisitions

Lantheus' recent strategic acquisitions of Life Molecular Imaging and Evergreen Theragnostics position the company well for future growth.

Negative Factors

Competitive Pressure

The initial guidance for 2025 suggests Pylarify can achieve low- to mid-single-digit growth despite reimbursement and competitive pressures.

Earnings Forecast

The updated earnings per share for the full year 2025 are lower than previous estimates.

Revenue Guidance

FY25 total revenue guidance was slightly below consensus expectations.

Lantheus Business Overview & Revenue Model

Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

How the Company Makes Money

Lantheus generates revenue primarily through the sale of its diagnostic and therapeutic imaging products. A significant portion of its income comes from the sales of DEFINITY, a widely used ultrasound contrast agent. Additionally, the company earns from its portfolio of radiopharmaceuticals, which includes products for PET and SPECT imaging procedures. Lantheus has established partnerships and distribution agreements which help in expanding the reach of its products to healthcare providers globally. Revenue is also supported by ongoing research and development efforts that lead to new product offerings and enhancements of existing products, ensuring a steady pipeline of innovative solutions in the medical imaging field.

Lantheus Financial Statement Overview

Summary

Lantheus exhibits strong financial health with robust revenue growth, high profitability margins, low leverage, and excellent cash flow generation. The income statement shows a significant revenue increase of 18.28%, and the balance sheet reflects minimal debt with a low debt-to-equity ratio. Cash flow management is effective with a free cash flow growth of 90.52%.

Income Statement

Lantheus demonstrates strong revenue growth, with a 18.28% increase from 2023 to 2024. The gross profit margin for 2024 is healthy at 64.43%, indicating effective cost management and profitability. The net profit margin improved to 20.37% in 2024, showing enhanced profitability. EBIT and EBITDA margins are robust at 29.79% and 29.79%, respectively, reflecting operational efficiency.

Balance Sheet

The company maintains a solid financial position with a low debt-to-equity ratio of 0.001, indicating minimal leverage. The return on equity is impressive at 28.72%, reflecting strong profitability relative to shareholder investments. The equity ratio of 54.94% indicates a healthy balance between equity and assets, suggesting financial stability.

Cash Flow

Lantheus has shown significant improvement in its free cash flow, growing by 90.52% from 2023 to 2024. Operating cash flow to net income ratio is strong at 1.74, indicating efficient cash generation from operations. The free cash flow to net income ratio of 1.58 underscores effective cash management and the ability to fund operations and growth.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.53B	1.30B	935.06M	425.21M	339.41M
	Gross Profit
988.29M	709.54M	581.70M	187.69M	138.76M
	EBIT
456.98M	364.64M	-13.44M	-76.09M	-4.20M
	EBITDA
515.27M	491.00M	81.83M	-25.00M	22.69M
	Net Income Common Stockholders
312.44M	326.66M	28.07M	-71.28M	-13.47M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
912.81M	713.66M	415.65M	98.51M	79.61M
	Total Assets
1.98B	1.65B	1.32B	863.78M	869.82M
	Total Debt
974.00K	616.95M	558.07M	174.76M	218.40M
	Net Debt
-911.84M	-96.71M	142.41M	76.25M	138.79M
	Total Liabilities
892.33M	835.26M	874.11M	399.35M	355.62M
	Stockholders Equity
1.09B	815.89M	447.15M	464.44M	514.21M
Cash Flow		Free Cash Flow
493.13M	258.70M	263.43M	41.78M	3.92M
	Operating Cash Flow
544.75M	305.26M	281.78M	53.92M	16.40M
	Investing Cash Flow
-226.01M	5.94M	-276.55M	3.68M	-4.91M
	Financing Cash Flow
-118.54M	-13.06M	311.69M	-39.33M	-21.86M

Lantheus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 103.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Positive. The current price of 103.64 is above the 20-day moving average (MA) of 98.52, above the 50-day MA of 95.55, and above the 200-day MA of 98.79, indicating a bullish trend. The MACD of 1.14 indicates Negative momentum. The RSI at 54.83 is Neutral, neither overbought nor oversold. The STOCH value of 69.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LNTH.

Lantheus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LNTH	80 Outperform	$6.82B	23.14	32.82%	―	18.32%	-5.33%
RDY	77 Outperform	$11.75B	18.19	18.51%	0.59%	13.26%	1.33%
NBIX	75 Outperform	$10.07B	31.36	14.16%	―	24.81%	33.67%
PRGO	53 Neutral	$3.39B	―	-3.53%	4.51%	-6.05%	-1677.05%
VTRS	52 Neutral	$9.18B	―	-3.24%	6.24%	-4.58%	-1269.23%
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
TEVA	50 Neutral	$16.04B	―	-25.44%	―	4.34%	-206.85%

Lantheus Corporate Events

Lantheus Completes Acquisition of Evergreen Theragnostics

On April 1, 2025, Lantheus Holdings, Inc. completed its acquisition of Evergreen Theragnostics, Inc., a move that enhances Lantheus’ capabilities across the radiopharmaceutical value chain. The acquisition, initially announced on January 28, 2025, includes Evergreen’s OCTEVY, a PET diagnostic imaging agent for neuroendocrine tumors, and a portfolio of theranostic pairs, as well as Evergreen’s radioligand therapy manufacturing infrastructure. This strategic acquisition positions Lantheus to better meet market demands and drive innovation, with potential milestone payments up to $727.5 million contingent on future achievements.

Lantheus Appoints Dr. Morrow to Board of Directors

Lantheus Holdings, Inc. announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., to its Board of Directors, effective February 1, 2025. Dr. Morrow, a seasoned pharmaceutical executive with extensive oncology expertise, will serve as an independent director and a member of the Science and Technology Committee. Her appointment comes during a period of growth for Lantheus, as it aims to enhance its strategic initiatives and innovative efforts in radiopharmaceuticals. Dr. Morrow’s experience is expected to bolster the company’s research and development capabilities, aligning with its vision to improve patient outcomes.

Lantheus to Acquire Evergreen Theragnostics for $250 Million

On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an agreement to acquire Evergreen Theragnostics for $250 million upfront and potential milestone payments of up to $752.5 million. This acquisition, expected to close in the second half of 2025, aims to enhance Lantheus’ capabilities as a fully integrated radiopharmaceutical company by adding Evergreen’s manufacturing infrastructure and expanding its oncology diagnostic pipeline. The addition of Evergreen’s assets, such as OCTEVY, a diagnostic agent targeting neuroendocrine tumors, is anticipated to complement Lantheus’ existing therapeutic offerings and strengthen its industry leadership. The merger is subject to customary closing conditions, including regulatory approvals.